Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

BACKGROUND: ALK tyrosine kinase inhibition has become a mainstay in the clinical management of ALK fusion positive NSCLC patients. Although ALK mutations can reliably predict the likelihood of response to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, they cannot reliably predict response...

Descripción completa

Detalles Bibliográficos
Autores principales: Couëtoux du Tertre, Mathilde, Marques, Maud, McNamara, Suzan, Gambaro, Karen, Hoffert, Cyrla, Tremblay, Lise, Bouchard, Nicole, Diaconescu, Razvan, Blais, Normand, Couture, Christian, Pelsser, Vincent, Wang, Hangjun, McIntosh, Laura, Hindie, Valérie, Parent, Stephane, Cortes, Laetitia, Breton, Yannick-André, Pottiez, Gwenael, Croteau, Pascal, Higenell, Valerie, Izzi, Luisa, Spatz, Alan, Cohen, Victor, Batist, Gerald, Agulnik, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006423/
https://www.ncbi.nlm.nih.gov/pubmed/32055239
http://dx.doi.org/10.1186/s12014-020-9269-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006423/
https://www.ncbi.nlm.nih.gov/pubmed/32055239
http://dx.doi.org/10.1186/s12014-020-9269-6

Ejemplares similares